We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Ground-breaking new cancer treatments have moved a step closer with the signing of a major agreement between the government and BioNTech SE.
Game-changing AI technology will be rolled out to all radiography departments in England in a matter of weeks – backed by £15.5 million in new Government funding.
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Projects granted during 2016 that have a primary purpose of basic research, oncology.
Projects granted during 2015 that have a primary purpose of basic research: oncology.
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
Innovative researchers working to tackle some of the hardest-to-treat cancers, including through the use of AI, have received a £2 million funding boost.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information on the NHS Cervical Screening Programme, including commissioning, quality assurance, education and training.
Information for patients, public and health care professionals.
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).